PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5350930

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the PATENT NUMBER: 9685579 previously recorded on Reel 046609 Frame 0822. Assignor(s) hereby confirms the ASSET PURCHASE BY WAY OF DEED.

CONVEYING PARTY DATA

Name	Execution Date
GW PHARMA LIMITED	03/29/2018

RECEIVING PARTY DATA

Name:	GW RESEARCH LIMITED
Street Address:	SOVEREIGN HOUSE
Internal Address:	VISION PARK
City:	HISTON, CAMBRIDGE, CAMBRIDGESHIRE
State/Country:	UNITED KINGDOM
Postal Code:	CB24 9BZ

PROPERTY NUMBERS Total: 5

Property Type	Number
Application Number:	14405950
Patent Number:	9675579
Application Number:	14899613
Patent Number:	9962341
Patent Number:	10039724

CORRESPONDENCE DATA

Fax Number: (617)646-8646

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6176468000
Email: patents_JohnV@wolfgreenfield.com, nicole.forgrave@wolfgreenfield.com
Correspondent Name: WOLF GREENFIELD & SACKS
Address Line 1: 600 ATLANTIC AVENUE
Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	H0664.700076US00
NAME OF SUBMITTER:	JOHN R. VAN AMSTERDAM
SIGNATURE:	/John R. Van Amsterdam/

DATE SIGNED:	01/30/2019

Total Attachments: 63

source=H0664.70076US00 -Transfer-of-Assets#page1.tif
source=H0664.70076US00 -Transfer-of-Assets#page2.tif
source=H0664.70076US00 -Transfer-of-Assets#page3.tif
source=H0664.70076US00 -Transfer-of-Assets#page4.tif
source=H0664.70076US00 -Transfer-of-Assets#page5.tif
source=H0664.70076US00 -Transfer-of-Assets#page6.tif
source=H0664.70076US00 -Transfer-of-Assets#page7.tif
source=H0664.70076US00 -Transfer-of-Assets#page8.tif
source=H0664.70076US00 -Transfer-of-Assets#page9.tif
source=H0664.70076US00 -Transfer-of-Assets#page10.tif
source=H0664.70076US00 -Transfer-of-Assets#page11.tif
source=H0664.70076US00 -Transfer-of-Assets#page12.tif
source=H0664.70076US00 -Transfer-of-Assets#page13.tif
source=H0664.70076US00 -Transfer-of-Assets#page14.tif
source=H0664.70076US00 -Transfer-of-Assets#page15.tif
source=H0664.70076US00 -Transfer-of-Assets#page16.tif
source=H0664.70076US00 -Transfer-of-Assets#page17.tif
source=H0664.70076US00 -Transfer-of-Assets#page18.tif
source=H0664.70076US00 -Transfer-of-Assets#page19.tif
source=H0664.70076US00 -Transfer-of-Assets#page20.tif
source=H0664.70076US00 -Transfer-of-Assets#page21.tif
source=H0664.70076US00 -Transfer-of-Assets#page22.tif
source=H0664.70076US00 -Transfer-of-Assets#page23.tif
source=H0664.70076US00 -Transfer-of-Assets#page24.tif
source=H0664.70076US00 -Transfer-of-Assets#page25.tif
source=H0664.70076US00 -Transfer-of-Assets#page26.tif
source=H0664.70076US00 -Transfer-of-Assets#page27.tif
source=H0664.70076US00 -Transfer-of-Assets#page28.tif
source=H0664.70076US00 -Transfer-of-Assets#page29.tif
source=H0664.70076US00 -Transfer-of-Assets#page30.tif
source=H0664.70076US00 -Transfer-of-Assets#page31.tif
source=H0664.70076US00 -Transfer-of-Assets#page32.tif
source=H0664.70076US00 -Transfer-of-Assets#page33.tif
source=H0664.70076US00 -Transfer-of-Assets#page34.tif
source=H0664.70076US00 -Transfer-of-Assets#page35.tif
source=H0664.70076US00 -Transfer-of-Assets#page36.tif
source=H0664.70076US00 -Transfer-of-Assets#page37.tif
source=H0664.70076US00 -Transfer-of-Assets#page38.tif
source=H0664.70076US00 -Transfer-of-Assets#page39.tif
source=H0664.70076US00 -Transfer-of-Assets#page40.tif
source=H0664.70076US00 -Transfer-of-Assets#page41.tif
source=H0664.70076US00 -Transfer-of-Assets#page42.tif
source=H0664.70076US00 -Transfer-of-Assets#page43.tif
source=H0664.70076US00 -Transfer-of-Assets#page44.tif
source=H0664.70076US00 -Transfer-of-Assets#page45.tif
source=H0664.70076US00 -Transfer-of-Assets#page46.tif

source=H0664.70076US00 -Transfer-of-Assets#page47.tif
source=H0664.70076US00 -Transfer-of-Assets#page48.tif
source=H0664.70076US00 -Transfer-of-Assets#page49.tif
source=H0664.70076US00 -Transfer-of-Assets#page50.tif
source=H0664.70076US00 -Transfer-of-Assets#page51.tif
source=H0664.70076US00 -Transfer-of-Assets#page52.tif
source=H0664.70076US00 -Transfer-of-Assets#page53.tif
source=H0664.70076US00 -Transfer-of-Assets#page54.tif
source=H0664.70076US00 -Transfer-of-Assets#page55.tif
source=H0664.70076US00 -Transfer-of-Assets#page56.tif
source=H0664.70076US00 -Transfer-of-Assets#page57.tif
source=H0664.70076US00 -Transfer-of-Assets#page58.tif
source=H0664.70076US00 -Transfer-of-Assets#page59.tif
source=H0664.70076US00 -Transfer-of-Assets#page60.tif
source=H066470076US00 Patent Assignment Cover Sheet#page1.tif
source=H066470076US00 Patent Assignment Cover Sheet#page2.tif
source=H066470076US00 Patent Assignment Cover Sheet#page3.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSET PURCHASE BY WAY OF DEED

CONVEYING PARTY DATA

Name	Execution Date
GW PHARMA LIMITED	03/29/2018

RECEIVING PARTY DATA

Name:	GW RESEARCH LIMITED
Street Address:	SOVEREIGN HOUSE
Internal Address:	VISION PARK
City:	HISTON, CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB24 9BZ

PROPERTY NUMBERS Total: 5

Property Type	Number
Application Number:	14405950
Patent Number:	9685579
Application Number:	14899613
Patent Number:	9962341
Application Number:	15321778

CORRESPONDENCE DATA

Fax Number: (617)646-8646
Phone: 6176468000
Email: patents_johnv@wolfgreenfield.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Correspondent Name: JOHN R. VAN AMSTERDAM
Address Line 1: 600 ATLANTIC AVENUE
Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	H0664.70070US00
NAME OF SUBMITTER:	JOHN R. VAN AMSTERDAM

Signature:	/John R. Van Amsterdam/
Date:	07/23/2018

Total Attachments: 60
source=H0664-Transfer-of-Assets#page1.tif
source=H0664-Transfer-of-Assets#page2.tif
source=H0664-Transfer-of-Assets#page3.tif
source=H0664-Transfer-of-Assets#page4.tif
source=H0664-Transfer-of-Assets#page5.tif
source=H0664-Transfer-of-Assets#page6.tif
source=H0664-Transfer-of-Assets#page7.tif
source=H0664-Transfer-of-Assets#page8.tif
source=H0664-Transfer-of-Assets#page9.tif
source=H0664-Transfer-of-Assets#page10.tif
source=H0664-Transfer-of-Assets#page11.tif
source=H0664-Transfer-of-Assets#page12.tif
source=H0664-Transfer-of-Assets#page13.tif
source=H0664-Transfer-of-Assets#page14.tif
source=H0664-Transfer-of-Assets#page15.tif
source=H0664-Transfer-of-Assets#page16.tif
source=H0664-Transfer-of-Assets#page17.tif
source=H0664-Transfer-of-Assets#page18.tif
source=H0664-Transfer-of-Assets#page19.tif
source=H0664-Transfer-of-Assets#page20.tif
source=H0664-Transfer-of-Assets#page21.tif
source=H0664-Transfer-of-Assets#page22.tif
source=H0664-Transfer-of-Assets#page23.tif
source=H0664-Transfer-of-Assets#page24.tif
source=H0664-Transfer-of-Assets#page25.tif
source=H0664-Transfer-of-Assets#page26.tif
source=H0664-Transfer-of-Assets#page27.tif
source=H0664-Transfer-of-Assets#page28.tif
source=H0664-Transfer-of-Assets#page29.tif
source=H0664-Transfer-of-Assets#page30.tif
source=H0664-Transfer-of-Assets#page31.tif
source=H0664-Transfer-of-Assets#page32.tif
source=H0664-Transfer-of-Assets#page33.tif
source=H0664-Transfer-of-Assets#page34.tif
source=H0664-Transfer-of-Assets#page35.tif
source=H0664-Transfer-of-Assets#page36.tif
source=H0664-Transfer-of-Assets#page37.tif
source=H0664-Transfer-of-Assets#page38.tif
source=H0664-Transfer-of-Assets#page39.tif
source=H0664-Transfer-of-Assets#page40.tif
source=H0664-Transfer-of-Assets#page41.tif
source=H0664-Transfer-of-Assets#page42.tif
source=H0664-Transfer-of-Assets#page43.tif
source=H0664-Transfer-of-Assets#page44.tif
source=H0664-Transfer-of-Assets#page45.tif
source=H0664-Transfer-of-Assets#page46.tif
source=H0664-Transfer-of-Assets#page47.tif
source=H0664-Transfer-of-Assets#page48.tif
source=H0664-Transfer-of-Assets#page49.tif
source=H0664-Transfer-of-Assets#page50.tif
source=H0664-Transfer-of-Assets#page51.tif
source=H0664-Transfer-of-Assets#page52.tif
source=H0664-Transfer-of-Assets#page53.tif

source=H0664-Transfer-of-Assets#page54.tif
source=H0664-Transfer-of-Assets#page55.tif
source=H0664-Transfer-of-Assets#page56.tif
source=H0664-Transfer-of-Assets#page57.tif
source=H0664-Transfer-of-Assets#page58.tif
source=H0664-Transfer-of-Assets#page59.tif
source=H0664-Transfer-of-Assets#page60.tif

RECEIPT INFORMATION

EPAS ID:	PAT5062044
Receipt Date:	07/23/2018

EXECUTION COPY

GW PHARMA LTD

- and –

GW RESEARCH LTD

ASSET PURCHASE BY WAY OF DEED

THIS DEED is dated 29 March 2018 and made

BETWEEN:

(1) **GW PHARMA LIMITED**, incorporated in England and Wales with company number 03704998, whose registered address is Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK ("GWP"); and

(2) **GW RESEARCH LIMITED**, incorporated in England and Wales with company number 03107561, whose registered address is Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK ("GWR").

BACKGROUND

(A) GWP carries on the business of the research and development of the pharmaceutical product known as Sativex®, the commercial manufacture of Sativex for supply to various third party collaboration partners, and the commercial manufacture of various other cannabinoid-based pipeline drug candidates for GWR.

(B) Between July 2007 and July 2013 GWP collaborated with Otsuka Pharmaceutical Co. Ltd ("Otsuka") regarding the research and pre-clinical development of various cannabinoid-based pipeline drug candidates under a written agreement ("Otsuka Research Collaboration and Licence Agreement").

(C) In October 2011 GWP and GWR entered into the GWP Research Collaboration and Licence Agreement (as defined below) pursuant to which GWR was licensed rights under certain Patent Rights and Know How (each as defined below) controlled by GWP to research and develop various cannabinoid-based pipeline drug candidates. Since July 2013, this collaboration has included the further research and development of the cannabinoid-based pipeline drug candidates the subject of the expired collaboration with Otsuka. These research and development activities were funded by GWR with no reimbursement of costs. Title in all intellectual property rights generated from these research activities prior to 30 June 2016 vested in GWP.

(D) The Patent Rights and Know How generated under the GWP Research Collaboration and Licence Agreement prior to June 2016 are the subject of the GWP Neuroprotection Licence Agreement (as defined below), which includes epilepsies and austism spectrum disorders, and which grants GWR exclusive rights to exploit the GWP Pipeline Intellectual Property (as defined below).

(E) The GWP Research Collaboration and Licence Agreement described in paragraph (C) has now expired and GWP wishes to sell and GWR wishes to purchase the GWP Pipeline Assets (as defined below) on the terms and conditions set out in this Agreement.

(F) GWP and GWR are both wholly owned subsidiaries of GW Pharmaceuticals plc.

THE PARTIES AGREE THAT

1. INTERPRETATION

1.1 DEFINITIONS

In this Agreement the following definitions shall apply unless the context requires otherwise:-

1.1.1 "Agreement" means this document including any and all schedules, appendices and other addenda to it as may be added and/or amended from time to time in accordance with the provisions of this document.

1.1.2 "Business Day" means a day (other than Saturday or Sunday) on which banks are open for ordinary banking business in the United Kingdom.

1.1.3 "Completion" means the completion of the sale and purchase of the GW Pipeline Assets in accordance with Clause 4.

1.1.4 "Confidential Information" means the following, subject to the exceptions set forth in Clause 7.1: (i) the terms and conditions of this Agreement, for which each Party will be considered a Disclosing Party and a Recipient Party; (ii) GWP Pipeline Know How for which GWP will be considered the Disclosing Party prior to Completion and GWR shall be considered the Disclosing Party following Completion; and (iii) Know How in Excluded Development and Manufacturing Intellectual Property, for which GWP will be considered the Disclosing Party.

1.1.5 "Consent" means any approval, consent, ratification, waiver or other authorisation.

1.1.6 "Delivered Documents" means (i) all Documents containing GWP Pipeline Know How, including all of the pre-clinical, clinical and regulatory files for the Pipeline Drug Candidates generated during the course of the GWP Research Collaboration and Licence Agreement, and all laboratory note books and reports from external third parties (including contract research organisations) relating to the development of the Pipeline Drug Candidates generated during the course of the GWP Research Collaboration and Licence

Agreement; (ii) executed copies (or where possible originals) of each of the GWP Pipeline Contracts; and (iii) registration certificates and prosecution history files in respect of the GWP Pipeline Patent Rights and the GWP Pipeline Trademarks, in each case that are in the possession or under the control of GWP.

1.1.7 "Documents" means reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, paper, notebooks, books, files, ledgers, records, tapes, discs, diskettes, CD-ROM, computer programs and documents thereof, computer information storage means, samples of material, other graphic or written data and any other media on which Know How can be permanently stored.

1.1.8 "Excluded Assets" means all assets owned by GWP at Completion which are not GWP Pipeline Assets including, inter alia, the assets of GWP relating to Sativex, and the Excluded Development and Manufacturing Intellectual Property.

1.1.9 "Excluded Development and Manufacturing Intellectual Property" means (i) any Patent Rights owned by or otherwise controlled by GWP at or after Completion which claim or otherwise cover the processes used by GWP from time to time to manufacture Pipeline Candidate Drugs or any one of them, (ii) the Patent Rights co-owned by GWP and Otsuka at Completion, (iii) the Know How owned by or otherwise controlled by GWP at or after Completion which relates to manufacture of any of the Pipeline Drug Candidates; and (iv) the Know How owned by or otherwise controlled by GWP at Completion which relates to any of the Pipeline Drug Candidates and which was generated during the course of the Otsuka Research Collaboration and Licence Agreement.

1.1.10 "GWP Neuroprotection Licence Agreement" means the Licence Agreement between GWP and GWR dated 1 October 2011, as amended from time to time.

1.1.11 "GWP Pipeline Assets" means (i) the GWP Pipeline Contracts, (ii) the GWP Pipeline Intellectual Property, and (iii) the Delivered Documents.

1.1.12 "GWP Pipeline Contracts" means the contracts entered in to by GWP prior to the Signature Date that are still in effect at the Signature Date and that relate to the development of one or more Pipeline Drug Candidates, including the contracts detailed in Schedule 1.1.12.

1.1.13 "GWP Pipeline Intellectual Property" means the GWP Pipeline Know How, GWP Pipeline Patent Rights and GWP Pipeline Trademarks.

1.1.14 "GWP Pipeline Know How" means all Know How owned by GWP at Completion: (i) required to practice the GWP Pipeline Patent Rights; or (ii) which is necessary or useful to enable GWR to continue to research, develop, seek regulatory approval for, or otherwise commercially exploit the Pipeline Dug Candidates, but excluding always from (i) and (ii) any and all Know How in Excluded Development and Manufacturing Intellectual Property.

1.1.15 "GWP Pipeline Patent Rights" means the Patent Rights filed by GWP under and pursuant to the terms of the GWP Research Collaboration and Licence Agreement, including those set out in Schedule 1.1.15 which includes published but not yet granted patent applications.

1.1.16 "GWP Pipeline Trademarks" means the registered trademarks and trademark applications set out in Schedule 1.1.16.

1.1.17 "GWP Research Collaboration and Licence Agreement" means the Research Collaboration and Licence Agreement between GWP and GWR dated 1 October 2011, as amended from time to time.

1.1.18 "Know How" means technical and other information which is not in the public domain, including information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, Materials, inventions, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports, manufacturing data or summaries and information contained in submissions to and information from ethical committees and regulatory authorities. Know How includes any rights including trade secrets, copyright, database or design rights protecting such Know How. The fact that an item is known to the public shall not be taken to preclude the possibility that a compilation including the item, and/or a development relating to the item, is not known to the public.

1.1.19 "Otsuka" has the meaning given to it in paragraph (B) of the Background.

1.1.20 "Otsuka Research Collaboration and Licence Agreement" has the meaning given to it in paragraph (B) of the Background.

1.1.21 "Patent Rights" means: (i) all national, regional and international patents and patent applications, including provisional patent applications; (ii) all patent applications filed

either from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from the foregoing patent applications (i) and (ii), including author certificates, inventor certificates, utility models, petty patents and design patents and certificates of invention; (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications (i), (ii) and (iii); and (v) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents.

1.1.22 "Party" and/or "Parties" means GWP and/or GWR.

1.1.23 "Pipeline Candidate Drugs" means the drug candidates described in Schedule 1.1.23.

1.1.24 "Signature Date" means the date of execution of this Agreement.

1.2 **Construction of certain references**

In this Agreement, where the context admits:

(i) references to Clauses and Schedules are references to clauses of and schedules to this Agreement, references to Paragraphs are unless otherwise stated, references to paragraphs of the schedule in which the reference appears, and references to this Agreement include the Schedules;

(ii) references to the singular shall include the plural and vice versa and reference to the masculine, the feminine and the neuter shall include all such genders;

(iii) "person" includes any individual, partnership, company, body corporate, state or agency of a state, and any unincorporated association or organisation, in each case whether or not having separate legal personality, and shall include any trade union; and

(iv) "company" includes any body corporate.

1.3 **Headings**

The headings and sub-headings are inserted for convenience only and shall not affect the construction of this Agreement.

1.4 **Schedules**

Each of the Schedules shall have effect as if set out herein.

2. **SALE OF ASSETS**

2.1 **Sale and purchase**

In accordance with the terms of this Agreement, GWP shall sell, and GWR shall purchase, all such right, title and interest of GWP in the following assets (in all cases except for the Excluded Assets) with effect from Completion:

2.1.1 subject to Clause 2.2, the GWP Pipeline Intellectual Property;

2.1.2 the Delivered Documents;

2.1.3 the benefit of each GWP Pipeline Contract.

2.2 **This Agreement constitutes an agreement to assign Patent Rights and Trademarks**

2.2.1 With respect to the GWP Pipeline Patent Rights, and notwithstanding any other provisions of this Agreement, the Agreement shall take effect as an agreement to sell such rights, with the sale being completed by the entry of GWP and GWR into such form of agreement(s) as may be required for effecting and recording the assignment at the relevant national or international patent offices, together with all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of infringement of such rights.

2.2.2 With respect to the GWP Pipeline Trademarks, and notwithstanding any other provisions of this Agreement, the Agreement shall take effect as an agreement to sell such rights, with the sale being completed by the entry of GWP and GWR into such form of agreement(s) as may be required for effecting and recording the assignment at the relevant national or international trademark offices, together with all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of infringement of such rights.

3. CONSIDERATION

3.1 Purchase price

The consideration for the sale and purchase of the GWP Pipeline Assets (including the agreement to assign the GW Pipeline Patent Rights and the GWP Pipeline Trademarks) shall be the amount of one pound Sterling (£1) ("Purchase Price"). The Purchase Price is payable in cash at Completion.

3.2 Value Added Tax

3.2.1 GWP and GWR acknowledge that section 43(1) of Value Added Tax Act 1994 will apply to the transfer of the GWP Pipeline Assets pursuant to this Agreement.

3.2.2 If, despite Clause 3.2.1, VAT is chargeable in connection with the transfer of the GWP Pipeline Assets under this Agreement, GWR shall pay GWP the amount of that VAT immediately on receipt of the relevant VAT invoice together with a copy of confirmation from HM Revenue & Customs that VAT is payable.

4. COMPLETION

4.1 Date and Time of Completion

Completion shall take place at 23.59 hours on the Signature Date immediately following the exchange of this Agreement. Following Completion GWP shall (subject to Clause 5 below):

4.1.1 Place GWR in possession of those of the GWP Pipeline Assets as are transferable by delivery whereupon title in those assets shall pass to GWR by delivery;

4.1.2 As soon as practical thereafter deliver to GWR such duly executed assignments and other instruments of transfer as agreed between GWP and GWR.

All GWP Pipeline Assets title to which is not transferable by delivery, and which are not the subject of assignments and other instruments delivered pursuant to Clause 4.1.2 shall, subject to Clause 5 below, transfer from GWP to GWR at 23.59 hours on the Signature Date by legal assignment under this Agreement.

5. TREATMENT OF GWP PIPELINE CONTRACTS

5.1 Assignment of benefit of Contracts capable of assignment

GWP shall with effect from Completion assign or hold to the order of GWR or procure the assignment to the order of GWR of all the GWP Pipeline Contracts which are capable of assignment without the Consent of other parties under the law applicable to the GWP Pipeline Contracts or under the terms of the GWP Pipeline Contracts.

5.2 Contracts not capable of assignment

In the case of those of the GWP Pipeline Contracts not so capable of assignment GWR shall, as soon as practicable following Completion use its best endeavours to obtain all necessary Consents for the assignment of the same or arrange the novation thereof.

5.3 Position pending assignment or novation

Unless and until such Consents are obtained or novation is effected GWP shall at its own expense following Completion, unless contractually prevented from so doing, sub-contract the GWP Pipeline Contracts concerned to GWR on the same terms (mutatis mutandis) and for the same remuneration as apply to the contracts concerned, so that the obligations and liabilities under such GWP Pipeline Contracts insofar as the same remain to be performed at Completion shall be effectively performed by GWR or by GWP on GWR's behalf and the full benefit of all contractual rights, benefits and claims thereunder arising after Completion shall vest in GWR and shall be held in trust by GWP for GWR absolutely. Where such holding in trust would result in the breach of any GWP Pipeline Contracts GWP and GWR shall make such other arrangements between themselves which will, without giving rise to such a breach, and so far as is practicable, secure rights for GWR equivalent to those it would enjoy from having transferred to it the benefit of the GWP Pipeline Contract with effect from Completion, or as soon as practicable thereafter.

6. TERMINATION OF EXISTING AGREEMENTS AND LICENCE GRANT

6.1 Terminations of existing agreements

On and with effect from 23.59 hours on the Signature Date, both the GWP Research Collaboration and Licence Agreement and the GWP Neuroprotection Licence Agreement shall terminate. With effect from 23.59 hours on the Signature Date, each of GWP and GWR (i) irrevocably releases and discharges the other from all its obligations and liabilities under or in connection with both the GWP Research Collaboration and Licence Agreement and the GWP Neuroprotection Licence

Agreement, and (ii) irrevocably waives any and all claims existing at the Signature Date of any nature whatsoever and howsoever arising (whether asserted or unasserted and whether presently known or unknown) including, without limitation, for payment or otherwise, which either may have against the other under or in connection with either the GWP Research Collaboration and Licence Agreement, the GWP Neuroprotection Licence Agreement or the termination of the same.

6.2 **Licence grant**

6.2.1 On and with effect from 23.59 hours on the Signature Date, GWP hereby grants to GWR under Excluded Development and Manufacturing Intellectual Property the exclusive, fully paid up, royalty free right to use the same in any way whatsoever for the purposes of researching, developing and seeking regulatory approvals for Pipeline Candidate Drugs. The grant of rights expressly excludes the rights for GWR to manufacture, have manufactured, commercialise or otherwise commercially exploit Pipeline Candidate Drugs.

6.2.2 GWR shall be entitled to sublicense the rights granted to it hereunder provided that GWR shall remain responsible for all of its obligations hereunder and if the acts or omissions of any of its sublicensees causes GWR to be in breach of this Agreement GWR shall be responsible therefor (with all the expenses consequences provided for under this Agreement and any implied consequences) regardless of any remedy which GWR may have against the sublicensee for breach of that sublicence.

6.2.3 The licence granted hereunder is perpetual and irrevocable. In the event of any breach by GWR of any of the terms of this Agreement GWP's sole remedy shall be to bring a claim for injunctive relief against GWR and/or to claim damages (no such breach shall entitle GWP to terminate this Agreement).

7. **CONFIDENTIALITY**

7.1 Except to the extent expressly authorised by this Agreement including in Clauses 7.2 and 7.3 or otherwise agreed in writing, each party in possession of Confidential Information ("Recipient Party") of the other Party ("Disclosing Party") shall maintain such Confidential Information as confidential and use it only for the purposes of this Agreement in accordance with this Clause 6. The term of maintaining confidentiality of all such information and the limitations on use shall be for a period equal to the longer of: (i) five (5) years after Completion; or (ii) for so long as the exceptions set out below in the next subsequent paragraph do not apply to the relevant Confidential Information. Each Party shall guard such Confidential Information using the same degree of care as it normally uses to guard its own confidential, proprietary information of like importance, but in

any event no less than reasonable care. Notwithstanding the foregoing, the Recipient Party shall be relieved of the confidentiality and limited use obligations of this Agreement to the extent that the Recipient Party establishes by written evidence that:

7.1.1 the Confidential Information (in the case of GWP, other than GWP Pipeline Know How) was previously known to that Party from sources other than the Disclosing Party at the time of disclosure and other than under an obligation of confidentiality;

7.1.2 the Confidential Information was generally available to the public or otherwise part of the public domain at the time of its disclosure; or

7.1.3 the Confidential Information became generally available to the public or otherwise part of the public domain after its disclosure to the Recipient Party other than through any act or omission of the Recipient Party in breach of this Agreement; or

7.1.4 the Confidential Information is acquired in good faith in the future by the Recipient Party from a third party who has a lawful right to disclose such information and who is not under an obligation of confidence to the Disclosing Party with respect to such information.

For clarity, specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Recipient Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the Recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Recipient Party unless the combination and its principles are in the public domain or in the possession of the Recipient Party.

7.2 Notwithstanding the above obligations of confidentiality and non-use a Recipient Party may:

7.2.1 disclose Confidential Information: (i) to the extent such disclosure is reasonably necessary to comply with the order of a court; or (ii) to the extent such disclosure is required to comply with a legal requirement;

7.2.2 disclose Confidential Information to such Recipient Party's employees, distributors, licensees, agents, consultants, clinical investigators, collaborators or contractors as such Recipient Party reasonably determines is necessary to receive the benefits of this Agreement or to fulfil its obligations pursuant to this Agreement; provided, however, any such persons must be obligated to substantially the same extent as set forth in Clause 7.1 to

hold in confidence and not make use of such Confidential Information for any purpose other than those permitted by this Agreement.

For clarity, nothing in this Clause 7 restricts either party from using or disclosing any of its own Confidential Information for any purpose whatsoever; provided that, for the purposes of this Agreement, from Completion forwards GWP Pipeline Know How shall be considered to be the Confidential Information of GWR.

7.3 Save as permitted in Clause 7.2, neither Party shall make any public announcement or statement to the public containing Confidential Information without the prior consent of the other. No such public announcements or statements shall be made without the prior review and consent of the appropriate individual designated for the purpose by the other Party.

8. PROVISIONS RELATING TO THIS AGREEMENT

8.1 Successors and assigns

This Agreement shall be binding upon and enure for the benefit of the successors of the Parties but shall not be assignable without the other Party's prior written consent.

8.2 Whole agreement and variations

8.2.1 This Agreement, together with any documents referred to in it, constitutes the whole agreement between the Parties relating to its subject matter and supersedes and extinguishes any prior drafts, agreements and undertakings, whether in writing or oral, relating to such subject matter and all conditions warranties and other terms and provisions which are implied into this Agreement by statute, common law or otherwise are hereby excluded.

8.2.2 No variation of this Agreement shall be effective unless made in writing and signed by each of the Parties.

8.3 Cumulative rights and other matters

8.3.1 The rights, powers, privileges and remedies provided in this Agreement are cumulative and are not exclusive of any rights, powers, privileges or remedies provided by law or otherwise.

8.3.2 No failure to exercise nor any delay in exercising any right, power, privilege or remedy under this Agreement shall in any way impair or affect the exercise thereof or operate as a waiver thereof in whole or in part.

8.3.3 No single or partial exercise of any right, power, privilege or remedy under this Agreement shall prevent any further or other exercise thereof or the exercise of any other right, power, privilege or remedy.

8.4 **Further assurance**

At any time after the date hereof either Party hereto shall at the request and cost of the other Party, execute or procure the execution of such documents and do or procure the doing of such acts and things as the requesting party may reasonably require for the purpose of vesting the GWP Pipeline Assets in GWR or otherwise giving effect to this Agreement.

8.5 **Invalidity**

If any provision of this Agreement shall be held to be illegal, void, invalid or unenforceable under the laws of any jurisdiction, the legality, validity and enforceability of the remainder of this Agreement in that jurisdiction shall not be affected, and the legality, validity and enforceability of the whole of this Agreement in any other jurisdiction shall not be affected.

8.6 **Counterparts**

This Agreement may be executed in any number of counterparts, which shall together constitute one Agreement. Any party may enter into this Agreement by signing any such counterpart.

9. **LAW AND JURISDICTION**

9.1 **English law**

This Agreement shall be governed by, and construed in accordance with, English law.

9.2 **Jurisdiction**

In relation to any legal action or proceedings to enforce this Agreement or arising out of or in connection with this Agreement each of the Parties irrevocably submits to the exclusive jurisdiction of the English courts and waives any objection to proceedings in such courts on the grounds of venue or on the grounds that the proceedings have been brought in an inappropriate forum.

This Agreement has been executed as a deed and is delivered and takes effect on the date stated at the beginning of it.

SCHEDULE 1.1.12ERROR! REFERENCE SOURCE NOT FOUND.

GWP PIPELINE CONTRACTS

Contract Number	Group Identifier	Counter Party	Department	Agreement Type	Unique Identifier	External Reference Number	GW Ref	Date of Logging
GWF-00675-MED-AME-00540	GWF	00675	MED	AME	540	GWCA1208	QBR01542/5	15 September 2016
GWF-00170-MED-CSA-01310	GWF	00170	MED	CSA	1310	N/A	N/A	21 February 2017
GWP-01153-DIR-CSA-0164S	GWP	01158	DIR	CSA	1645	N/A	N/A	
GWP-01065-E&P-SOW-02475	GWP	01065	E&P	SOW	2475	DUDSD20170613v2	N/A	08 September 2017

SCHEDULE 1.1.15

GWP PATENT RIGHTS

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
Cannabionoids for use in the treatment of neuro-degenerative diseases or disorders	GW Pharma Limited	Hong Kong	P0045HK	14111255.1	06/Nov/2014			Pending	29/Jun/2020	P137443HK
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Albania	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809AL
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Austria	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809AT
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Belgium	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809BE
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Bulgaria	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809BG
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Brazil	P0048BR	BR112014030406 8	10/Jun/2013			Pending	10/Jun/2018	P138809BR

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Canada	P0048CA	2874968	10/Jun/2013			Pending	10/Jun/2018	P138809CA
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Switzerland	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809CH
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Cyprus	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809CY
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Czech Republic	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809CZ
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Germany	P0048EP	EP13729798.2	10/Jun/2013	602013009393.8	13/Jul/2016	Granted	10/Jun/2018	P138809DE
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Denmark	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809DK
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Estonia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809EE
SYNERGISTIC THERAPIES	GW Pharma	Europe	P0048EP	EP13729798.2	10/Jun/201	EP2858633	13/Jul/201	Nationalis		P138809EP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
FOR NEUROPROTECTION	Limited				3		6	ed		
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Spain	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809ES
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Finland	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809FI
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	France	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809FR
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	United Kingdom	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809GB1
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Greece	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809GR
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Croatia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809HR
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Hungary	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809HU

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Ireland	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809IE
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Iceland	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809IS
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Italy	P0048EP	EP13729798.2	10/Jun/2013	502016000081741	13/Jul/2016	Granted	10/Jun/2018	P138809IT
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Japan	P0048JP	2015-515588	10/Jun/2013	6284525	08/Feb/2018	Granted	09/Feb/2021	P138809JP
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Lithuania	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809LT
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Luxembourg	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809LU
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Latvia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809LV
SYNERGISTIC THERAPIES	GW Pharma	Monaco	P0048EP	EP13729798.2	10/Jun/201	EP2858633	13/Jul/201	Granted	10/Jun/201	P138809M

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
FOR NEUROPROTECTION	Limited				3		6		8	C
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Macedonia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809MK
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Malta	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809MT
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Mexico	P0048MX	MX/A/2014/014839	10/Jun/2013			Pending		P138809MX
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Netherlands	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809NL
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Norway	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809NO
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Poland	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809PL
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Portugal	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809PT

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Romania	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809RO
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Republic of Serbia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809RS
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Sweden	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809SE
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Slovenia	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809SI
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Slovak Republic	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809SK
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	San Marino	P0048EP	EP13729798.2	10/Jun/2013	EP2858633	13/Jul/2016	Granted	10/Jun/2018	P138809SM
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	Turkey	P0048EP	EP13729798.2	10/Jun/2013	TR 2016 09966 T4	13/Jul/2016	Granted	10/Jun/2018	P138809TR
SYNERGISTIC THERAPIES	GW Pharma	USA	P0048U	14/405,950	10/Jun/201			Pending		P138809US

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
FOR NEUROPROTECTION	Limited		S		3					
SYNERGISTIC THERAPIES FOR NEUROPROTECTION	GW Pharma Limited	International	P0048WO	PCT/GB2013/051519	10/Jun/2013			Pending		P138809WO
TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	GW Pharma Limited	Europe	P0512EP	EP14717843.8	14/Apr/2014			Pending	14/Apr/2019	P138847EP
TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	GW Pharma Limited	USA	P0512US	US14/785,055	14/Apr/2014	9,685,579	13/Jun/2017	Granted	13/Dec/2020	P138847US
TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	GW Pharma Limited	International	P0512WO	PCT/GB2014/051159	14/Apr/2014			Granted		P138847WO
USE OF PHYTOCANNABINOIDS	GW Pharma Limited and	Europe	P0614EP	EP14732613.6	19/Jun/2014			Pending	19/Jun/2018	P139030EP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	Otsuka Pharmaceutical Co. Limited									
USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	GW Pharma Limited and Otsuka Pharmaceutical Co Limited	United Kingdom	P0614GB	GB1310909.5	19/Jun/2013	GB2516814	31/Aug/2016	Granted	19/Jun/2018	P139030GB
USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	GW Pharma Limited and Otsuka Pharmaceutical Co. Limited	USA	P0614US	14/899,598	19/Jun/2014			Pending		P139030US
USE OF PHYTOCANNABINOIDS FOR INCREASING	GW Pharma Limited and Otsuka	International	P0614WO	PCT/GB2014/051888	19/Jun/2014			Granted		P139030WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
RADIOSENSITIVITY IN THE TREATMENT OF CANCER	Pharmaceutical Co. Limited									
THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	GW Pharma Limited	Europe	P0613EP	EP14732614.4	19/Jun/2014			Pending	19/Jun/2018	P139031EP
THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	GW Pharma Limited	United Kingdom	P0613GB1	1406473.7	10/Apr/2014	GB2516335	08/Feb/2017	Granted	10/Apr/2019	P139031GB1
THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	GW Pharma Limited	USA	P0613WO	14/899,613	19/Jun/2014			Pending		P139031US
THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF	GW Pharma Limited	International	P0613WO	PCT/GB2014/051889	19/Jun/2014			Granted		P139031WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
OVARIAN CARCINOMA										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	Australia	P0049AU	2015275886	17/Jun/2015			Pending	17/Jun/2019	P139599AU
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	Brazil	P0049BR	BR112016029506 4	17/Jun/2015			Pending	17/Jun/2018	P139599BR
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT	GW Pharma Limited	Canada	P0049CA	2952994	17/Jun/2015			Pending	17/Jun/2018	P139599CA

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	Europe	P0049EP	EP15732886.5	17/Jun/2015			Pending	17/Jun/2018	P139599EP
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	United Kingdom	P0049	GB1410771.8	17/Jun/2014			Pending		P139599GB
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT	GW Pharma Limited	United Kingdom	P0049GB1	GB1506550.1	17/Apr/2015			Pending		P139599GB1

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	Japan	P0049JP	2016-573558	17/Jun/2015			Pending		P139599JP
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	Mexico	P0049MX	MX/A/2016/016459	17/Jun/2015			Pending		P139599MX
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT	GW Pharma Limited	New Zealand	P0049NZ	727509	17/Jun/2015			Pending	17/Jun/2019	P139599NZ

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	P0049US	14/741,783	17/Jun/2015	9,474,726	25/Oct/2016	Granted	25/Apr/2020	P139599US
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	P0049US1	US15/284,766	17/Jun/2015			Pending		P139599USC1
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT	GW Pharma Limited	USA	P0049US2	US15/449,084	04/Oct/2016			Pending		P139599USC2

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	P0049US3	US15/449,124	04/Oct/2016			Pending		P139599USC3
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	P0049US4	US15/449,185	04/Oct/2016			Pending		P139599USC4
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT	GW Pharma Limited	USA	P0049US5	US15/449,204	04/Oct/2016			Pending		P139599USC5

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	P0049US6	US15/449,177	04/Oct/2016			Pending		P139599USC6
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	International	P0049WO	PCT/GB2015/051775	17/Jun/2015			Nationalised		P139599WO
ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF	GW Pharma Limited	Europe	P0050EP	EP15733502.7	26/Jun/2015			Pending	26/Jun/2018	P139601EP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
CANCER										
ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	GW Pharma Limited	United Kingdom	P0050	1411465.6	27/Jun/2014			Pending		P139601GB
ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	GW Pharma Limited	USA	P0050US	US15/321,766	26/Jun/2015			Pending		P139601US
ACTIVE PHARMACEUTICAL INGREDIENT (API)	GW Pharma Limited	International	P0050WO	PCT/GB2015/051876	26/Jun/2015			Nationalised		P139601WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER										
7-OH-CBD DIABETES	GW Pharma Limited	Europe	P0051EP	EP15733513.4	29/Jun/2015			Pending	29/Jun/2018	P139602EP
7-OH-CBD DIABETES	GW Pharma Limited	United Kingdom	P0051GB	1411467.2	27/Jun/2014			Pending		P139602GB
7-OH-CBD DIABETES	GW Pharma Limited	USA	P0051GB	US15/321,778	29/Jun/2015			Pending		P139602US
7-OH-CBD DIABETES	GW Pharma Limited	International	P0051GB	PCT/GB2015/051893	29/Jun/2015			Nationalised		P139602WO
USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE	GW Pharma Limited	Europe	P0052EP	EP15733514.2	29/Jun/2015			Pending	29/Jun/2018	P139603EP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
TREATMENTOF EPILEPSY										
USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENTOF EPILEPSY	GW Pharma Limited	United Kingdom	P0052GB	1411496.1	27/Jun/2014			Pending		P139603GB
USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENTOF EPILEPSY	GW Pharma Limited	USA	P0052US	US15/321,819	29/Jun/2015			Pending		P139603US
USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE	GW Pharma Limited	International	P0052WO	PCT/GB2015/051894	29/Jun/2015			Nationalised		P139603WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
TREATMENTOF EPILEPSY										
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Europe	P0056/EP	EP15784112.3	14/Oct/2015			Pending	14/Oct/2018	P139625EP
USE OF CANNABIDIOL IN THE TREATMENT OF INTRACTABLE EPILEPSY	GW Pharma Limited	United Kingdom	P0056	GB1418166.3	14/Oct/2014			Pending		P139625GB
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	P0056/US	15/519,233	14/Oct/2015			Pending		P139625US
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	International	P0056	PCT/GB2015/053029	14/Oct/2015			Nationalised		P139625WO
USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	GW Pharma Limited	Europe	P0055/EP	EP15784113.1	14/Oct/2015			Pending	14/Oct/2018	P139626EP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
USE OF CANNABIDIOL IN THE TREATMENT OF INTRACTABLE EPILEPSY	GW Pharma Limited	United Kingdom	P0055	1418169.7	14/Oct/2014			Pending		P139626GB
USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	GW Pharma Limited	USA	P0055/US	15/519,244	14/Oct/2015			Pending		P139626US
USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	GW Pharma Limited	International	P0055	PCT/GB2015/053030	14/Oct/2015			Nationalised		P139626WO
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Australia	P0054/AU	2015332208	14/Oct/2015			Pending	14/Oct/2019	P139627AU
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Brazil	P0054/BR	BR 11 2017 007767 1	14/Oct/2015			Pending	14/Oct/2018	P139627BR
USE OF CANNABIDIOL IN THE TREATMENT OF	GW Pharma Limited	Canada	P0054	2,963,202	14/Oct/2015			Pending	14/Oct/2018	P139627CA

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Europe	P0054/EP	EP15784107.3	14/Oct/2015			Pending	14/Oct/2018	P139627EP
USE OF CANNABIDIOL IN THE TREATMENT OF INTRACTABLE EPILEPSY	GW Pharma Limited	United Kingdom	P0054	GB1418170.5	14/Oct/2014			Pending		P139627GB
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Gulf Cooperation	P0054GC	GC2015-30192	13/Oct/2015			Pending	01/Jan/2019	P139627GC
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Israel	P0054	251526	14/Oct/2015			Pending		P139627IL
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Japan	P0054	2017-520526	14/Oct/2015			Pending		P139627JP

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Mexico	P0054	MX/A/2017/004763	14/Oct/2015			Pending		P139627MX
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	New Zealand	P0054	730980	14/Oct/2015			Pending		P139627NZ
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	P0054	14/881,954	13/Oct/2015			Pending		P139627US
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	International	P0054	PCT/GB2015/053024	14/Oct/2015			Nationalised		P139627WO
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Australia	P0053/AU	2015332212	14/Oct/2015			Pending	14/Oct/2019	P139628AU
USE OF CANNABINOIDS IN THE TREATMENT OF	GW Pharma Limited	Brazil	P0053	BR 11 2017 007777 9	14/Oct/2015			Pending	14/Oct/2018	P139628BR

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Canada	P0053	2,963,208	14/Oct/2015			Pending	14/Oct/2018	P139628CA
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Europe	P0053/EP	EP15784111.5	14/Oct/2015			Pending	14/Oct/2018	P139628EP
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	United Kingdom	P0053	GB1418171.3	14/Oct/2014			Pending		P139628GB
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Gulf Cooperation	P0053GC	GC2015-30191	13/Oct/2015			Pending	01/Jan/2019	P139628GC
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Israel	P0053	251529	14/Oct/2015			Pending		P139628IL

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Japan	P0053	2017-520530	14/Oct/2015			Pending		P139628JP
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	Mexico	P0053	MX/A/2017/004762	14/Oct/2015			Pending		P139628MX
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	New Zealand	P0053	730982	14/Oct/2015			Pending		P139628NZ
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	P0053	14/881,969	13/Oct/2015			Pending		P139628US
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	P0053US1	US15/449,402	13/Oct/2015			Pending		P139628USC1
USE OF CANNABINOIDS IN THE TREATMENT OF	GW Pharma Limited	USA	P0053US2	US15/449,535	13/Oct/2015			Pending		P139628USC2

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
EPILEPSY										
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	International	P0053	PCT/GB2015/053028	14/Oct/2015			Nationalised		P139628WO
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	Australia	P0057/AU	2015332220	14/Oct/2015			Pending	14/Oct/2019	P139629AU
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	Brazil	P0057/BR	BR 11 2017 007774 4	14/Oct/2015			Pending	14/Oct/2018	P139629BR
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE	GW Pharma Limited	Canada	P0057	2,963,211	14/Oct/2015			Pending	14/Oct/2018	P139629CA

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
DISEASES										
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	Europe	P0057/EP	EP15784121.4	14/Oct/2015			Pending	14/Oct/2018	P139629EP
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	Israel	P0057	251530	14/Oct/2015			Pending		P139629IL
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	Japan	P0057/JP	2017-520535	14/Oct/2015			Pending		P139629JP
USE OF CANNABINOIDS IN THE TREATMENT OF	GW Pharma	Mexico	P0057	MX/A/2017/0047	14/Oct/201			Pending		P139629M

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
DEGENERATIVE SKELETAL MUSCLE DISEASES	Limited			61	5					X
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	New Zealand	P0057	730985	14/Oct/2015			Pending		P139629NZ
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	USA	P0057	15/518,297	14/Oct/2015			Pending		P139629US
USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	GW Pharma Limited	International	P0057	PCT/GB2015/053044	14/Oct/2015			Nationalised		P139629WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
Absence Seizures	GW Pharma Limited	Australia	P0058AU	2015275887	17/Jun/2015			Pending	17/Jun/2019	P139634AU
Absence Seizures	GW Pharma Limited	Brazil	P0058BR	BR112016029498 0	17/Jun/2015			Pending	17/Jun/2018	P139634BR
Absence Seizures	GW Pharma Limited	Canada	P0058CA	2,952,858	17/Jun/2015			Pending	17/Jun/2018	P139634CA
Absence Seizures	GW Pharma Limited	Europe	P0058EP	EP15732887.3	17/Jun/2015			Pending	17/Jun/2018	P139634EP
Absence Seizures	GW Pharma Limited	Japan	P0058JP	2016-573518	17/Jun/2015			Pending		P139634JP
Absence Seizures	GW Pharma Limited	Mexico	P0058MX	MX/A/2016/016460	17/Jun/2015			Pending		P139634MX
Absence Seizures	GW Pharma Limited	New Zealand	P0058NZ	727511	17/Jun/2015			Pending	17/Jun/2019	P139634NZ
Absence Seizures	GW Pharma	USA	P0058U	14/741,829	17/Jun/201			Pending		P139634US

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
	Limited		S		5					
Absence Seizures	GW Pharma Limited	International	P0058WO	PCT/GB2015/051776	17/Jun/2015			Nationalised		P139634WO
Dravet trilogy	GW Research Limited	United Kingdom	P0059	GB1510664.4	17/Jun/2015			Pending		P139635GB
CBDA for use in epilepsy	GW Pharma Limited	Australia	P0060/AU	2016305545	29/Jul/2016			Pending	29/Jul/2020	P139636AU
CBDA for use in epilepsy	GW Pharma Limited	Brazil	P0060/BR	BR 1120180026026	29/Jul/2016			Pending	29/Jul/2018	P139636BR
CBDA for use in epilepsy	GW Pharma Limited	Canada	P0060/CA	2,992,802	29/Jul/2016			Pending	29/Jul/2019	P139636CA
CBDA for use in epilepsy	GW Pharma Limited	Europe	P0060/EP	EP16747593.8	29/Jul/2016			Pending	29/Jul/2018	P139636EP
CBDA for use in epilepsy	GW Pharma	United	P0060	1514079.1	10/Aug/20			Pending		P139636GB

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
	Limited	Kingdom			15					
CBDA for use in epilepsy	GW Pharma Limited	Japan	P0060/JP	NOT YET KNOWN	29/Jul/2016			Pending		P139636JP
CBDA for use in epilepsy	GW Pharma Limited	Mexico	P0060/MX	MX/A/2018/001472	29/Jul/2016			Pending		P139636MX
CBDA for use in epilepsy	GW Pharma Limited	New Zealand	P0060/NZ	739200	29/Jul/2016			Pending	29/Jul/2020	P139636NZ
CBDA for use in epilepsy	GW Pharma Limited	USA	P0060/US	15/751,563	29/Jul/2016			Pending		P139636US
CBDA for use in epilepsy	GW Pharma Limited	International	P0060WO	PCT/GB2016/052340	29/Jul/2016			Nationalised		P139636WO
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	Australia	P0061AU	2016320505	08/Sep/2016			Pending	08/Sep/2020	P139637AU
USE OF CANNABINOIDS IN THE TREATMENT OF	GW Pharma	Canada	P0061W	NOT YET	08/Sep/20			Pending	08/Sep/20	P139637CA

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
MENTAL DISORDERS	Limited		O	KNOWN	16				19	
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	Europe	P0061WO	EP16766051.3	08/Sep/2016			Pending	08/Sep/2018	P139637EP
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	United Kingdom	P0061GB	GB1515986.6	09/Sep/2015			Pending		P139637GB
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	New Zealand	P0061NZ	739933	08/Sep/2016			Pending	08/Sep/2020	P139637NZ
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	USA	P0061WO	PCT/GB2016/052778	08/Sep/2016			Not Yet Filed		P139637US
USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GW Pharma Limited	International	P0061WO	PCT/GB2016/052778	08/Sep/2016			Nationalised		P139637WO

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
CANNABINOIDS IN SKIN INFLAMMATION	GW Pharma Limited	United Kingdom	P0062	GB1517215.8	29/Sep/2015			Pending		P139639GB
CANNABINOIDS IN SKIN INFLAMMATION	GW Pharma Limited	International	P0062WO	PCT/GB2016/053027	29/Sep/2016			Pending		P139639WO
USE OF CANNABINOIDS IN THE TREATMENT OF MULTIPLE MYELOMA	GW Research Limited	United Kingdom	P0069	1614522.9	25/Aug/2016			Pending		P139650GB
SPC application - Pharmaceutical compositions containing cannabinoids	GW Pharma Limited	Finland	P0008	C20140030	28/May/2014			Granted		S125615FI
Pharmaceutical formulations (Sativex product)	GW Pharma Limited	Switzerland	SPC P0017	1542657	14/Feb/2014	1542657	31/Mar/2016	Granted	14/Aug/2023	S125649CH
Supplementary Protection Certificate	GW Pharma Limited	France	P0017	1542657	21/Mar/2014	1542657	08/Aug/2014	Granted	14/Aug/2023	S125649FR
Pharmaceutical formulations (Sativex product)	GW Pharma Limited	Ireland	P0017 - SPC	1542657	10/Sep/2014	2014/049	17/Oct/2016	Granted	13/Aug/2023	S125649IE

Invention	Applicant	Country	Client Ref.	Application No.	Application Date	Grant No.	Grant Date	Status	Next Renewal	HGF Ref.
Supplementary Protection Certificate	GW Pharma Limited	Italy	P0017	UB2013001319	26/Jul/2013	1319	28/Oct/2013	Granted	14/Aug/2023	S125649IT
Pharmaceutical formulations (Sativex product	GW Pharma Limited	Luxembourg	P0017	92233	26/Jun/2013	92233	26/Aug/2013	Granted	31/Aug/2023	S125649LU
Supplementary Protection Certificate based on P-375224	GW Pharma Limited	Poland	P0017/PL SPC	0245/0215220	10/Sep/2013	EP215220	10/Jan/2017	Granted	17/Aug/2023	S125649PL

SCHEDULE 1.1.16

GWP TRADEMARKS

Mark	Application No.	Registration No.	Country
BICANNEX	2304383	2304383	United Kingdom
CANNABIDEX	2304389	2304389	United Kingdom
CANNABIDEX	85/379901	4319562	United States of America
CANNABINOID RESEARCH INSTITUTE	2304395	2304395	United Kingdom
CANNABINOID RESEARCH INSTITUTE	Not yet assigned	Not yet assigned	Madrid Protocol (TM)
CANNABINOID RESEARCH INSTITUTE	87/771739	Not yet registered	United States of America
CANNAVAR	2304386	2304386	United Kingdom
CANNIVEX	2338253	2338253	United Kingdom
CANTIVEX	3477346	3477346	European Community
CANTIVEX	2338259	2338259	United Kingdom
CANTIVEX	824459	824459	Madrid Protocol (TM)
CANTIVEX	824459	824459	Australia
CANTIVEX	824459	824459	Bulgaria
CANTIVEX	824459	824459	Cyprus
CANTIVEX	824459	824459	Czech Republic

Mark	Application No.	Registration No.	Country
CANTIVEX	824459	824459	Estonia
CANTIVEX	824459	824459	Hungary
CANTIVEX	824459	824459	Latvia
CANTIVEX	824459	824459	Liechtenstein
CANTIVEX	824459	824459	Lithuania
CANTIVEX	824459	824459	Norway
CANTIVEX	824459	824459	Poland
CANTIVEX	824459	824459	Romania
CANTIVEX	824459	824459	Serbia
CANTIVEX	824459	824459	Singapore
CANTIVEX	824459	824459	Slovakia
CANTIVEX	824459	824459	Slovenia
CANTIVEX	824459	824459	Switzerland
CANTIVEX	824459	824459	Turkey
CANTIVEX	824459	824459	Bahrain
CANTIVEX	824459	824459	Egypt
CANTIVEX	824459	824459	Oman
CANTIVEX	134769		Kuwait
CANTIVEX	77784		Qatar
CANTIVEX	187477		Saudi Arabia

Mark	Application No.	Registration No.	Country
CANTIVEX	181113		United Arab Emirates
CEPAEDEX	3009941	3009941	United Kingdom
CEPAEDEX	85/959272	4673758	United States of America
COMBIDIOL	2598672	2598672	United Kingdom
COMBIDIOL	1119094	1119094	Madrid Protocol (TM)
COMBIDIOL	1119094	1119094	European Community
COMBIDIOL	1119094	1119094	United States of America
COMBIDIOLEX	2598673	2598673	United Kingdom
COMBIDIOLEX	1123182	1123182	Madrid Protocol (TM)
COMBIDIOLEX	1123182	1123182	European Community
COMBIDIOLEX	1123182	1123182	United States of America
CRI	3274822	Not yet registered	United Kingdom
CRI	87/771644	Not yet registered	United States of America
DUCANNEX	003478054	003478054	European Community
DUCANNEX	2304387	2304387	United Kingdom
EMESCANN	2304392	2304392	United Kingdom
EPIDIOLEX	1818624	Not yet registered	Canada
EPIDIOLEX	12639373	12639373	European Community
EPIDIOLEX	3013236	3013236	United Kingdom
EPIDIOLEX	3068471	3068471	United Kingdom

Mark	Application No.	Registration No.	Country
EPIDIOLEX	1208519	1208519	Madrid Protocol (TM)
EPIDIOLEX	1226800	1226800	Madrid Protocol (TM)
EPIDIOLEX	1208519	1208519	Australia
EPIDIOLEX	1208519	1208519	China
EPIDIOLEX	1208519	1208519	India
EPIDIOLEX	1208519	1208519	Israel
EPIDIOLEX	1208519	1208519	Japan
EPIDIOLEX	1208519	1208519	Mexico
EPIDIOLEX	1208519	1208519	New Zealand
EPIDIOLEX	1208519	1208519	Norway
EPIDIOLEX	1208519	1208519	Serbia
EPIDIOLEX	1208519	1208519	Switzerland
EPIDIOLEX	1208519	1208519	Turkey
EPIDIOLEX	1226800	1226800	Australia
EPIDIOLEX	1226800	1226800	China
EPIDIOLEX	1226800	1226800	European Community
EPIDIOLEX	1226800	1226800	India
EPIDIOLEX	1226800	1226800	Israel
EPIDIOLEX	1226800	1226800	Japan
EPIDIOLEX	1226800	1226800	Mexico

Mark	Application No.	Registration No.	Country
EPIDIOLEX	1226800	1226800	New Zealand
EPIDIOLEX	1226800	1226800	Norway
EPIDIOLEX	1226800	1226800	Serbia
EPIDIOLEX	1226800	1226800	Switzerland
EPIDIOLEX	1226800	1226800	Turkey
EPIDIOLEX	1226800	1226800	United States of America
EPIDIOLEX	86/007888	4484943	United States of America
EPIDIOLEX	914114077	Not yet registered	Brazil
EPIDIOLEX	914114107	Not yet registered	Brazil
EPIVARIN	86/243559	4726412	United States of America
EPIVARINEX	3044567	3044567	United Kingdom
EPIVARINEX	1222832	1222832	Madrid Protocol (TM)
EPIVARINEX	86/242714	4726409	United States of America
EPIVARINEX	1222832	1222832	European Community
NABIDIOLEX	3477353	3477353	European Community
NABIDIOLEX	2331741	2331741	United Kingdom
NABIDIOLEX	816176	816176	Madrid Protocol (TM)
NABIDIOLEX	85/380134	4366678	United States of America
NABIDIOLEX	816176	816176	Australia
NABIDIOLEX	816176	816176	Bulgaria

Mark	Application No.	Registration No.	Country
NABIDIOLEX	816176	816176	China
NABIDIOLEX	816176	816176	Cyprus
NABIDIOLEX	816176	816176	Czech Republic
NABIDIOLEX	816176	816176	Estonia
NABIDIOLEX	816176	816176	Hungary
NABIDIOLEX	816176	816176	Latvia
NABIDIOLEX	816176	816176	Liechtenstein
NABIDIOLEX	816176	816176	Lithuania
NABIDIOLEX	816176	816176	Norway
NABIDIOLEX	816176	816176	Poland
NABIDIOLEX	816176	816176	Romania
NABIDIOLEX	816176	816176	Serbia
NABIDIOLEX	816176	816176	Singapore
NABIDIOLEX	816176	816176	Slovakia
NABIDIOLEX	816176	816176	Slovenia
NABIDIOLEX	816176	816176	Switzerland
NABIDIOLEX	816176	816176	Turkey
NABIDIOLEX	1196173	676968	Canada
NABIDIOLEX	1248283	1248283	India
NABIDIOLEX	167829	167829	Israel

Mark	Application No.	Registration No.	Country
NABIDIOLEX	704224	704224	New Zealand
NEODIOL	2581189	2581189	United Kingdom
NEODIOL	1099310	1099310	Madrid Protocol (TM)
NEODIOL	1099310	1099310	Japan
NEODIOL	1099310	1099310	United States of America
NEODIOLEX	2581191	2581191	United Kingdom
NEODIOLEX	1099312	1099312	Madrid Protocol (TM)
NEODIOLEX	1099312	1099312	European Community
NEODIOLEX	1099312	1099312	Japan
NEODIOLEX	1099312	1099312	United States of America
NEONABIDEX	2581192	2581192	United Kingdom
NEONABIDEX	1099311	1099311	Madrid Protocol (TM)
NEONABIDEX	1099311	1099311	European Community
NEONABIDEX	1099311	1099311	Japan
NEONABIDEX	1099311	1099311	United States of America
SATORIVEX	2655595	2655595	United Kingdom
TETRA V ARINEX	1506906	1506906	India
TETRANABINEX	3477387	3477387	European Community
TETRANABINEX	2331742	2331742	United Kingdom
TETRANABINEX	820250	820250	Madrid Protocol (TM)

Mark	Application No.	Registration No.	Country
TETRANABINEX	85/380022	4366677	United States of America
TETRANABINEX	820250	820250	Australia
TETRANABINEX	820250	820250	Bulgaria
TETRANABINEX	820250	820250	China
TETRANABINEX	820250	820250	Cyprus
TETRANABINEX	820250	820250	Czech Republic
TETRANABINEX	820250	820250	Estonia
TETRANABINEX	820250	820250	Hungary
TETRANABINEX	820250	820250	Japan
TETRANABINEX	820250	820250	Latvia
TETRANABINEX	820250	820250	Liechtenstein
TETRANABINEX	820250	820250	Lithuania
TETRANABINEX	820250	820250	Norway
TETRANABINEX	820250	820250	Poland
TETRANABINEX	820250	820250	Romania
TETRANABINEX	820250	820250	Serbia
TETRANABINEX	820250	820250	Singapore
TETRANABINEX	820250	820250	Slovakia
TETRANABINEX	820250	820250	Slovenia
TETRANABINEX	820250	820250	Switzerland

Mark	Application No.	Registration No.	Country
TETRANABINEX	820250	820250	Turkey
TETRANABINEX	1196172	677375	Canada
TETRANABINEX	1248282	1248282	India
TETRANABINEX	167830	167830	Israel
TETRANABINEX	704223	704223	New Zealand
TETRAVARINEX	2422557	2422557	United Kingdom
TETRAVARINEX	918111	918111	Madrid Protocol (TM)
TETRAVARINEX	918111	918111	Australia
TETRAVARINEX	918111	918111	Bulgaria
TETRAVARINEX	918111	918111	China
TETRAVARINEX	918111	918111	European Community
TETRAVARINEX	918111	918111	Japan
TETRAVARINEX	918111	918111	Norway
TETRAVARINEX	918111	918111	Romania
TETRAVARINEX	918111	918111	Switzerland
TETRAVARINEX	918111	918111	Turkey
TETRAVARINEX	918111	918111	United States of America
THERACANNEX	2993764	2993764	European Community
THERACANNEX	2304371	2304371	United Kingdom
THERACANNEX	1154748	1154748	Madrid Protocol (TM)

Mark	Application No.	Registration No.	Country
THERACANNEX	1154748	1154748	Bahrain
THERACANNEX	1154748	1154748	Egypt
THERACANNEX	1154748	1154748	Oman
THERACANNEX	137289		Kuwait
THERACANNEX	79508		Qatar
THERACANNEX	192148		Saudi Arabia
THERACANNEX	186707		United Arab Emirates
THERACANNOID	2304390	2304390	United Kingdom
THERACANNOL	2304373	2304373	United Kingdom

SCHEDULE 1.1.23

PIPELINE CANDIDATE DRUGS

All cannabinoid-based drug candidates evaluated by GWR during the course of the GWP Research Collaboration and Licence Agreement, including CBD, CBDV, CBDA, THC, THCV, THCA, CBN, CBC, CBG, CBGV, CBGA, all in both BDS, purified BDS (-/-), pure (semi-synthetic) and pure (synthetic) form

EXECUTED as a deed by **GW PHARMA LTD** acting by , a director, in the presence of:

Name: LAURA A FOUGMAN
Occupation: EXECUTIVE ASST.
Address 21 CHURCHILL ROAD
LONDON NW2 5ED

Director

EXECUTED as a deed by **GW RESEARCH LTD** acting by , a director, in the presence of:

Name: LAURA FOUGMAN
Occupation: EXECUTIVE ASST.
Address 21 CHURCHILL ROAD
LONDON NW2 5ED

Director